VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$2.97 USD
+0.05 (1.71%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.96 -0.01 (-0.34%) 6:08 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VTGN 2.97 +0.05(1.71%)
Will VTGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTGN
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
VTGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Other News for VTGN
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference ...
Vistagen to Present at the BTIG Virtual Biotechnology Conference | VTGN Stock News
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership | VTGN Stock News
Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News
Vistagen appoints Elissa Cote as Chief Corporate Development Officer